ciclesonide (Alvesco) vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
ciclesonide (Alvesco)
Marketed by Azurity Pharmaceuticals and partners
NCT00163397 · Phase 3 · completed
This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)
Result source: NCT00174720
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | ciclesonide (Alvesco) | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00174720 | —Trial running · NCT04651777 |
| Trough FEV1, change | —Not posted · NCT00174720 | 0.1 vs 0.1vs FF/VINCT029246885 other results
|
| ACQ-5, change | —Not posted · NCT00174720 | —Trial running · NCT04651777 |
| OCS dose reduction | —Not posted · NCT00174720 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
Trough FEV1, change
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
ACQ-5, change
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
OCS dose reduction
- ciclesonide (Alvesco)
- —Not posted · NCT00174720
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ciclesonide (Alvesco): 4 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ciclesonide (Alvesco) | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Dropout rate | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result11.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | 7.7%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Discontinued due to AEs | —a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result5.1% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | 0.7%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Serious AEs | 0%a NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 show 1 more result0.8% NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy | 4.4%100/31.25/25 mcgb NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Most frequent reported AEs | a headaches/migraine 23.8% (placebo 22.7%) respiratory infections 19% (placebo 18.2%) bilateral otitis media 4.8% (placebo 0%) NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4 | 100/31.25/25 mcgb nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
- bPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ciclesonide (Alvesco)
show 1 more result
fluticasone furoate/umeclidinium/vilanterol
show 5 more results
show 3 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ciclesonide (Alvesco)'s landscape · fluticasone furoate/umeclidinium/vilanterol's landscape